Syndax Pharmaceuticals Inc [SNDX] stock prices are down -0.86% to $16.06 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SNDX shares have gain 2.95% over the last week, with a monthly amount drifted -1.89%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On August 05, 2025, BTIG Research reiterated its Buy rating and revised its price target to $56 on the stock. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $18 on July 10, 2025. UBS initiated its recommendation with a Buy and recommended $37 as its price target on October 24, 2024. Jefferies started tracking with a Buy rating for this stock on June 28, 2024, and assigned it a price target of $37. In a note dated January 31, 2024, Scotiabank downgraded an Sector Perform rating on this stock and revised its target price from $36 to $23.
The stock price of Syndax Pharmaceuticals Inc [SNDX] has been fluctuating between $8.58 and $22.50 over the past year. Currently, Wall Street analysts expect the stock to reach $32.33 within the next 12 months. Syndax Pharmaceuticals Inc [NASDAQ: SNDX] shares were valued at $16.06 at the most recent close of the market. An investor can expect a potential return of 101.31% based on the average SNDX price forecast.
Analyzing the SNDX fundamentals
The Syndax Pharmaceuticals Inc [NASDAQ:SNDX] reported sales of 78.18M for trailing twelve months, representing a surge of 984.51%. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -4.34%, Pretax Profit Margin comes in at -4.28%, and Net Profit Margin reading is -4.28%. To continue investigating profitability, this company’s Return on Assets is posted at -0.56, Equity is -1.3 and Total Capital is -0.7. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Syndax Pharmaceuticals Inc [NASDAQ:SNDX]’s Current Ratio is 4.71. As well, the Quick Ratio is 4.55, while the Cash Ratio is 0.96. Considering the valuation of this stock, the price to sales ratio is 17.70, the price to book ratio is 8.78.
Transactions by insiders
Recent insider trading involved Metzger Michael A, Chief Executive Officer, that happened on Sep 08 ’25 when 0.16 million shares were sold. Director, MICHAEL METZGER completed a deal on Sep 08 ’25 to buy 0.16 million shares. Meanwhile, Director Podlesak Dennis sold 19200.0 shares on Aug 18 ’25.
